GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » EBITDA Margin %

Lin BioScience (ROCO:6696) EBITDA Margin % : 0.00% (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lin BioScience's EBITDA for the six months ended in Jun. 2023 was NT$-440.99 Mil. Lin BioScience's Revenue for the six months ended in Jun. 2023 was NT$0.00 Mil. Therefore, Lin BioScience's EBITDA margin for the quarter that ended in Jun. 2023 was 0.00%.


Lin BioScience EBITDA Margin % Historical Data

The historical data trend for Lin BioScience's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience EBITDA Margin % Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lin BioScience's EBITDA Margin %

For the Biotechnology subindustry, Lin BioScience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lin BioScience's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lin BioScience's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lin BioScience's EBITDA Margin % falls into.



Lin BioScience EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lin BioScience's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1071.403/0
= %

Lin BioScience's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-440.985/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lin BioScience  (ROCO:6696) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Lin BioScience EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Lin BioScience's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lin BioScience (ROCO:6696) Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines